ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bannan, S.
Right arrow Articles by Martin, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bannan, S.
Right arrow Articles by Martin, P. G.

Ann Thorac Surg 1997;63:663-668
© 1997 The Society of Thoracic Surgeons


Original Article: Cardiovascular

Low Heparinization With Heparin-Bonded Bypass Circuits: Is It a Safe Strategy?

Sally Bannan, MMedSc, Amanda Danby, HND, Dahlia Cowan, BSc, Saeed Ashraf, FRCS, Paul G. Martin, PhD

Department of Cardiothoracic Surgery, Killingbeck Hospital, and Research School of Medicine, University of Leeds, Leeds, United Kingdom

Accepted for publication September 30, 1996.

Background. The use of heparin-bonded cardiopulmonary bypass circuits with reduced doses of heparin sodium has been shown to give hemostatic benefits to the patient. However, fears persist that the use of less heparin may put the patient at risk for thrombotic events. This work tested the hypothesis that heparin-bonded circuits per se are effective in preserving cells and reducing thrombin generation when a reduced dose of heparin is used in vitro.

Methods. Simulated extracorporeal circulation was carried out using the same unit of fresh heparinized (1.1 U/mL) human blood to simultaneously perfuse a heparin-bonded circuit and a nonbonded circuit. Samples were taken at 30, 60, 120, and 360 minutes and analyzed for markers of cell activation and thrombin generation.

Results. The concentrations of platelet and white blood cell activation markers were found to be significantly lower in the heparin-bonded circuits compared with the nonbonded circuits. In addition, markers of thrombin generation were significantly lower in bonded circuits. Scanning electron microscopy revealed fewer adherent cells and less debris on the bonded surface compared with the nonbonded surface.

Conclusions. Cell activation and thrombin generation were significantly reduced as a result of the presence of immobilized heparin in a system of cardiopulmonary bypass with reduced plasma heparin. However, evidence of contact activation in the bonded circuits was found after 120 minutes, indicating that anticoagulation in the system was not adequate. This becomes more important clinically where the extrinsic pathway of coagulation is also involved.




This article has been cited by other articles:


Home page
PerfusionHome page
C. Baufreton, J. L. de Brux, P. Binuani, J.-J. Corbeau, J. B. Subayi, J. C. Daniel, and P. Treanor
A combined approach for improving cardiopulmonary bypass in coronary artery surgery: a pilot study
Perfusion, December 1, 2002; 17(6): 407 - 413.
[Abstract] [PDF]


Home page
J Biomater ApplHome page
H. P. Wendel, N. Hauser, F. Briquet, and G. Ziemer
Hemocompatibility of Medical Connectors with Biopassive or Bioactive Surface Coatings
J Biomater Appl, July 1, 2002; 17(1): 5 - 17.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr
Mechanisms and attenuation of hemostatic activation during extracorporeal circulation
Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
S. Svenmarker, E. Sandstrom, T. Karlsson, S. Haggmark, E. Jansson, M. Appelblad, R. Lindholm, and T. Aberg
Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits
Eur. J. Cardiothorac. Surg., January 1, 2001; 19(1): 47 - 53.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Nakajima, K. Kawazoe, K. Ishibashi, Y. Kubota, T. Sasaki, H. Izumoto, and T. Nitatori
Reduction of heparin dose is not beneficial to platelet function
Ann. Thorac. Surg., July 1, 2000; 70(1): 186 - 190.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
H. P. Wendel and G. Ziemer
Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation
Eur. J. Cardiothorac. Surg., September 1, 1999; 16(3): 342 - 350.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. Wahba, A. Philipp, R. Behr, and D. E. Birnbaum
Heparin-Coated Equipment Reduces the Risk of Oxygenator Failure
Ann. Thorac. Surg., May 1, 1998; 65(5): 1310 - 1312.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. C. Hill, S. Bannan, and P. G. Martin
Low heparinization and heparin-bonded circuits.
Ann. Thorac. Surg., October 1, 1997; 64(4): 1221 - 1222.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 by The Society of Thoracic Surgeons.